What is the duration of maintenance pembrolizumab (pembrolizumab) therapy in patients with metastatic endometrial cancer?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 12, 2025 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

From the Research

Pembrolizumab maintenance therapy for metastatic endometrial cancer should be continued for up to 2 years (35 cycles) in patients who demonstrate clinical benefit and do not experience unacceptable toxicity, as supported by the most recent and highest quality study 1.

Rationale for Duration

The duration of pembrolizumab maintenance therapy is based on the design of clinical trials that established its efficacy in this setting. The study by 1 demonstrated that the addition of pembrolizumab to standard chemotherapy resulted in significantly longer progression-free survival than with chemotherapy alone in patients with advanced or recurrent endometrial cancer.

Treatment Administration

Each cycle of pembrolizumab consists of 200 mg administered intravenously every 3 weeks. Treatment may be discontinued earlier if disease progression occurs or if the patient experiences intolerable side effects that cannot be managed with dose interruptions or supportive care.

Considerations for Extended Treatment

Some patients may continue treatment beyond 2 years if they are still deriving benefit, though this would be considered on a case-by-case basis. The decision to extend treatment should be based on individual patient factors, including response to therapy, toxicity, and overall health status.

Mechanism of Action

Pembrolizumab works by enhancing T-cell responses against tumor cells, with evidence suggesting that these immunologic effects may persist even after discontinuation of the drug. This mechanism of action supports the use of pembrolizumab as a maintenance therapy to sustain clinical benefit in patients with metastatic endometrial cancer.

Key Points

  • Pembrolizumab maintenance therapy should be continued for up to 2 years (35 cycles) in patients with clinical benefit and no unacceptable toxicity.
  • Each cycle consists of 200 mg administered intravenously every 3 weeks.
  • Treatment may be discontinued earlier due to disease progression or intolerable side effects.
  • Extended treatment beyond 2 years may be considered on a case-by-case basis.
  • Pembrolizumab's mechanism of action supports its use as a maintenance therapy to sustain clinical benefit.

References

Research

Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer.

The New England journal of medicine, 2023

Related Questions

What is the evidence for the combination of gemcitabine, carboplatin, and pembrolizumab in metastatic endometrial cancer?
What evidence supports the use of maintenance pembrolizumab (Keytruda) in metastatic endometrial cancer?
What is the recommended first‑line systemic therapy, dosing schedule, monitoring, toxicity management, and alternative options for an adult patient with metastatic or unresectable endometrial carcinoma who has progressed after or is unsuitable for conventional chemotherapy, regarding lenvatinib (Lenvima) plus pembrolizumab (Keytruda)?
What were the design, dosing regimen, and outcomes of the NRG‑GY018 phase III trial evaluating pembrolizumab (Keytruda) combined with carboplatin‑paclitaxel chemotherapy in patients with advanced (stage III–IVB) or recurrent endometrial carcinoma?
Is it safe for a patient taking lenvatinib (Lenvima) and pembrolizumab (Keytruda) with a normal complete blood count to undergo dental cleaning and scaling?
What is the frequency of liver function test monitoring in anti-tubercular (antituberculosis) therapy?
What is the frequency of liver function test monitoring in fluconazole (antifungal medication) therapy?
What is the frequency at which Liver Function Tests (LFTs) should be monitored in hospitalized patients with abnormal results?
What is the kinetics of Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) change duration?
What is the workup for autoimmune disease in a patient with episcleritis (inflammation of the episclera)?
What increases the risk of first bite syndrome after parotid (salivary gland) surgery, specifically parotidectomy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.